Berbamine application beyond cancer

The main purpose of this review was to ascertain the clinical application and future non oncological uses of Berbaminebamine (BERBAMINE). Berbaminebamine, as a STAT3 (signal transducer and activator of transcription) inhibitor, antioxidant, anti-inflammatory and modulator of many signalling pathways, should be investigated in autoimmune diseases.  Berbaminebamine has been found to have pharmacological activity in the following cancers: breast cancer, lung cancer, prostate cancer, pancreatic cancer, ovarian cancer, glioblastoma, colon cancer, bladder cancer, chronic myeloid leukemia, hepatocellular carcinoma, triple negative breast cancer and osteosarcoma. Ischemic reperfusion injury, melanoma, COVID-19 and allergy diseases are among the conditions for which it is beneficial. It may aid in the treatment of obesity, metabolic syndrome, inflammatory syndrome, sepsis, COVID-19, dengue fever, Nipah virus infection, influenza, solid tumors, lymphoma, cancer, hematological malignancies, skin inflammatory disorder and atopic dermatitis.  BERBAMINE can be used as versatile molecule in alcoholic liver disease, diabetic nephropathy and antiviral, anti-inflammatory

A brief study of Nox 4 inhibitors in diabetic nephropathy

The purpose of the study was to find the merits and demerits of NADPH oxidase 4 (Nox 4) inhibitors. Nox inhibitors are tested from natural sources like green tea, plumbagin, Chinese formulas like Baoshenfang, Cudrania tricuspidata, Huangqi decoction and synthetic dual Nox inhibitors. Some of them activate and regulate AMP-activated protein kinase (AMPK). Some chunk the high glucose activated alleyway, dawdling the succession of diabetic nephropathy (DN). Overall, the benefits of NOX are: reducing oxidative damage, improving renal function, reducing podocyte injury, preventing interstitial fibrosis, regulating AMPK which inhibits reactive oxygen species (ROS) and transforming growth factor-beta (TGF-beta), decreasing inflammation due to high glucose, protecting mesangial cells, decreasing collagen synthesis, and reducing glomerular hypertrophy. While targeting NOX in renal impairment, off-target effects, especially cardiovascular effects, are one of the major hurdles since diabetes mellitus (DM) is associated with co-morbid cardiovascular problems

Peroxisome proliferator-activated receptors and thiazolidinediones in diabetic nephropathy

Diabetic nephropathy is global problem with several drugs into trial without much success the current article highlights the role of thiazolidinedione’s in diabetic nephropathy by scrutinizing and reconnoitring the cellular and intracellular mechanism and shielding action and the role of peroxisome proliferator-activated gamma receptors (PPARγ) receptors. Not only anti-diabetic action but renal protective effect with evidence based study has been highlighted. PPAR γ-is versatile target having numerous benefits and mainly preventing fibrosis in diabetic experimental model and some clinical case report yet, the benefits are not up to mark, since renal failure itself causes volume expansion and the thiazolidinedione’s (TZDs) also preserve salt and water and lead to congestive heart failure which constraints its clinical application. Dual activators and balaglitazone selective PPAR modulator are having upcoming potential for treatment of diabetic nephropathy. Further detail investigation on such drug is needed to explore. However adverse effect like heart failure, osteoporosis and volume expansion effect over-rides the beneficial effect thus limiting its clinical use of currently available TZDs

Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study an international prospective cohort study

We aimed to determine the impact of pre-operative isolation on postoperative pulmonary complications after elective surgery during the global SARS-CoV-2 pandemic. We performed an international prospective cohort study including patients undergoing elective surgery in October 2020. Isolation was defined as the period before surgery during which patients did not leave their house or receive visitors from outside their household. The primary outcome was postoperative pulmonary complications, adjusted in multivariable models for measured confounders. Pre-defined sub-group analyses were performed for the primary outcome. A total of 96,454 patients from 114 countries were included and overall, 26,948 (27.9%) patients isolated before surgery. Postoperative pulmonary complications were recorded in 1947 (2.0%) patients of which 227 (11.7%) were associated with SARS-CoV-2 infection. Patients who isolated pre-operatively were older, had more respiratory comorbidities and were more commonly from areas of high SARS-CoV-2 incidence and high-income countries. Although the overall rates of postoperative pulmonary complications were similar in those that isolated and those that did not (2.1% vs 2.0%, respectively), isolation was associated with higher rates of postoperative pulmonary complications after adjustment (adjusted OR 1.20, 95%CI 1.05–1.36, p = 0.005). Sensitivity analyses revealed no further differences when patients were categorised by: pre-operative testing; use of COVID-19-free pathways; or community SARS-CoV-2 prevalence. The rate of postoperative pulmonary complications increased with periods of isolation longer than 3 days, with an OR (95%CI) at 4–7 days or ≥ 8 days of 1.25 (1.04–1.48), p = 0.015 and 1.31 (1.11–1.55), p = 0.001, respectively. Isolation before elective surgery might be associated with a small but clinically important increased risk of postoperative pulmonary complications. Longer periods of isolation showed no reduction in the risk of postoperative pulmonary complications. These findings have significant implications for global provision of elective surgical care. We aimed to determine the impact of pre-operative isolation on postoperative pulmonary complications after elective surgery during the global SARS-CoV-2 pandemic. We performed an international prospective cohort study including patients undergoing elective surgery in October 2020. Isolation was defined as the period before surgery during which patients did not leave their house or receive visitors from outside their household. The primary outcome was postoperative pulmonary complications, adjusted in multivariable models for measured confounders. Pre-defined sub-group analyses were performed for the primary outcome. A total of 96,454 patients from 114 countries were included and overall, 26,948 (27.9%) patients isolated before surgery. Postoperative pulmonary complications were recorded in 1947 (2.0%) patients of which 227 (11.7%) were associated with SARS-CoV-2 infection. Patients who isolated pre-operatively were older, had more respiratory comorbidities and were more commonly from areas of high SARS-CoV-2 incidence and high-income countries. Although the overall rates of postoperative pulmonary complications were similar in those that isolated and those that did not (2.1% vs 2.0%, respectively), isolation was associated with higher rates of postoperative pulmonary complications after adjustment (adjusted OR 1.20, 95%CI 1.05–1.36, p = 0.005). Sensitivity analyses revealed no further differences when patients were categorised by: pre-operative testing; use of COVID-19-free pathways; or community SARS-CoV-2 prevalence. The rate of postoperative pulmonary complications increased with periods of isolation longer than 3 days, with an OR (95%CI) at 4–7 days or ≥ 8 days of 1.25 (1.04–1.48), p = 0.015 and 1.31 (1.11–1.55), p = 0.001, respectively. Isolation before elective surgery might be associated with a small but clinically important increased risk of postoperative pulmonary complications. Longer periods of isolation showed no reduction in the risk of postoperative pulmonary complications. These findings have significant implications for global provision of elective surgical care